Strong PhII data in triglyceride reduction attracts partners to Essentialis
This article was originally published in Scrip
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
You may also be interested in...
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.